OverviewSuggest Edit

MeiraGTx is a gene therapy company, which is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The Company is pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. MeiraGTx is also developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration.

TypePublic
Founded2015
HQLondon, GB
Websitemeiragtx.com

Latest Updates

Employees (est.) (Sept 2019)130(+20%)
Revenue (FY, 2019)$13.3 M
Share Price (Jan 2021)$16.4 (-2%)
Cybersecurity ratingAMore

Key People/Management at MeiraGTx

Keith R. Harris

Keith R. Harris

Chairman of the Board
Alexandria Forbes

Alexandria Forbes

President and Chief Executive Officer, Director
Richard Giroux

Richard Giroux

Chief Operating Officer and Chief Financial Officer
Ellen Hukkelhoven

Ellen Hukkelhoven

Independent Board Member
Christine Sheehy

Christine Sheehy

SVP, Global Integration
Stuart Naylor

Stuart Naylor

Chief Development Officer
Show more

MeiraGTx Office Locations

MeiraGTx has offices in London, New York and Leiden
London, GB (HQ)
7NQ 92 Britannia Walk
Leiden, NL
Biopartner Gebouw 2 19 J.H. Oortweg
New York, NY, US
450 E 29th St 15th Floor
Show all (3)

MeiraGTx Financials and Metrics

MeiraGTx Revenue

MeiraGTx's revenue was reported to be $13.29 m in FY, 2019
USD

Revenue (Q3, 2020)

5.1m

Net income (Q3, 2020)

(6.4m)

EBIT (Q3, 2020)

(8.4m)

Market capitalization (8-Jan-2021)

713.3m

Closing stock price (8-Jan-2021)

16.4

Cash (30-Sept-2020)

179.1m
MeiraGTx's current market capitalization is $713.3 m.
Annual
USDFY, 2018FY, 2019

Revenue

13.3m

General and administrative expense

44.5m46.7m

R&D expense

33.6m24.9m

Operating expense total

78.1m71.6m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

785.0k2.0m3.6m4.2m2.5m5.1m

General and administrative expense

17.4m6.6m8.5m13.4m9.9m11.8m11.5m8.9m

R&D expense

7.8m8.1m13.0m9.8m4.6m8.1m16.2m4.6m

Operating expense total

25.2m14.7m21.5m23.2m14.5m19.9m27.7m13.5m
Annual
USDFY, 2018FY, 2019

Cash

68.1m227.2m

Accounts Receivable

23.3m

Prepaid Expenses

1.9m4.5m

Current Assets

74.7m269.0m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

102.1m88.6m227.3m204.3m253.3m210.4m194.8m179.1m

Accounts Receivable

28.0m24.4m26.6m

Prepaid Expenses

1.6m2.0m1.8m3.3m6.2m3.5m7.3m4.0m

Current Assets

104.0m91.3m231.2m212.9m271.1m251.0m235.2m217.9m
Annual
USDFY, 2018FY, 2019

Net Income

(82.9m)(54.7m)

Depreciation and Amortization

2.1m2.2m

Accounts Payable

(2.1m)(8.7k)

Cash From Operating Activities

(58.9m)20.0m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(46.4m)(61.8m)(18.0m)(38.8m)(49.3m)(15.7m)(41.1m)(47.5m)

Depreciation and Amortization

1.0m1.5m499.6k1.0m1.6m815.4k1.8m2.8m

Accounts Payable

(2.4m)(2.3m)304.7k266.9k1.4m3.9m(704.3k)480.9k

Cash From Operating Activities

(36.4m)(47.4m)82.2m60.4m42.0m(12.4m)(25.3m)(34.4m)
USDQ2, 2018

EV/EBIT

-8.3 x

EV/CFO

-5.8 x

Financial Leverage

1.1 x
Show all financial metrics

MeiraGTx Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

MeiraGTx Online and Social Media Presence

Embed Graph

MeiraGTx News and Updates

MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia

Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET

MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 3rd Annual HealthCONx Co…

MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in a fireside chat at the Piper Sandler …

MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment

Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months

MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)

LONDON and NEW YORK, Oct. 03, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy in develop…

MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting

- Nine-Month Follow-Up Data to be Presented - - Nine-Month Follow-Up Data to be Presented -
Show more

MeiraGTx Blogs

MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual Meeting

12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented LONDON and NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that twelve-month results from the ongoing Phase 1/2

MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer

LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert K. Zeldin , M.D. as chief medical officer (CMO). A clinical immunologist by training, Dr.

MeiraGTx Reports First Quarter 2020 Financial Results

LONDON and NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on recent progress.

MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference

LONDON and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Virtual Bank of America Securities

MeiraGTx Reports Full Year 2019 Financial Results

MeiraGTx Reports Full Year 2019 Financial Results Content Import Wed, 03/11/2020 - 17:01 MeiraGTx Reports Full Year 2019 Financial Results March 11, 2020 This release is a backfill from a News Wire Earnings LONDON and NEW YORK, March 11, 2020 (GL…

MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa Content Import Mon, 03/02/2020 - 08:31 MeiraGTx Announces Priority M…
Show more

MeiraGTx Frequently Asked Questions

  • When was MeiraGTx founded?

    MeiraGTx was founded in 2015.

  • Who are MeiraGTx key executives?

    MeiraGTx's key executives are Keith R. Harris, Alexandria Forbes and Richard Giroux.

  • How many employees does MeiraGTx have?

    MeiraGTx has 130 employees.

  • What is MeiraGTx revenue?

    Latest MeiraGTx annual revenue is $13.3 m.

  • What is MeiraGTx revenue per employee?

    Latest MeiraGTx revenue per employee is $102.2 k.

  • Who are MeiraGTx competitors?

    Competitors of MeiraGTx include Caribou Biosciences, Editas Medicine and Evolutionary Genomics.

  • Where is MeiraGTx headquarters?

    MeiraGTx headquarters is located at 7NQ 92 Britannia Walk, London.

  • Where are MeiraGTx offices?

    MeiraGTx has offices in London, New York and Leiden.

  • How many offices does MeiraGTx have?

    MeiraGTx has 3 offices.